Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 228 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zmax Clear all

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Interleukin-12, Paromomycin sulfate, Azithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Azithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2007
U.S. locations: 51
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 31 more

Conditions: Pre-Bronchiolitis Obliterans Syndrome
Interventions: ARINA-1, Standard of care only; Drug · Other
Lead sponsor: Renovion, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more

Conditions: COVID-19
Interventions: Hydroxychloroquine, Azithromycin; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 45 Years and older
Enrollment: 1,550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Murray, Utah • Salt Lake City, Utah

Conditions: Endometritis, Wound Infection, Abscess, Surgical Site Infection
Interventions: Azithromycin and standard of care, Placebo and standard of care; Drug
Lead sponsor: Alan Tita; Other
Eligibility: 14 Years and older · Female only
Enrollment: 2,013 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 9
States / cities: Birmingham, Alabama • New Orleans, Louisiana • Jackson, Mississippi + 6 more

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Azithromycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Groton, Connecticut

Conditions: COVID-19
Interventions: Hydroxychloroquine, Indomethacin, Zithromax Oral Product; Drug
Lead sponsor: Perseverance Research Center, LLC; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Scottsdale, Arizona • New Orleans, Louisiana

Conditions: Blepharitis
Interventions: Tobradex ST, Azasite; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Meibomian Gland Dysfunction
Interventions: Azasite; Drug
Lead sponsor: Philadelphia Eye Associates; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: First Trimester Abortion
Interventions: Azithromycin, Doxycycline, Metronidazole, Placebo; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Silver Spring, Maryland

Conditions: Preterm Premature Rupture of Membrane
Interventions: Azithromycin 500 mg, Azithromycin Oral Product; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 14 Years to 65 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Azithromycin Tablets 600 mg, Zithromax® Tablets 600 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
Interventions: Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide, Amoxicillin-clavulanate + Macrolide, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir, Amoxicillin-clavulanate + Ceftazidime + Macrolide, Meropenem + Macrolide; Drug · Other · Biological + 1 more
Lead sponsor: UMC Utrecht; Other
Eligibility: 28 Days and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 11
States / cities: Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more

Conditions: Healthy
Interventions: cefdinir (Omnicef), azithromycin; Drug
Lead sponsor: Abbott; Industry
Eligibility: 4 Years to 8 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2003
U.S. locations: 3
States / cities: Scottsdale, Arizona • St. Petersburg, Florida • Miamiville, Ohio

Conditions: Dry Eye, Neuropathic Eye Pain, Ocular Microbiome, Depression, Anxiety
Interventions: Azithromycin Oral Product, Placebo Oral; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Gonorrhea
Interventions: zoliflodacin, ceftriaxone, azithromycin; Drug
Lead sponsor: Global Antibiotics Research and Development Partnership; Other
Eligibility: 12 Years and older
Enrollment: 1,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 2 more

Conditions: Bacterial Conjunctivitis
Interventions: AzaSite, Vehicle; Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 12 Months and older
Enrollment: 685 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 32
States / cities: Flagstaff, Arizona • Cudahy, California • Petaluma and Santa Rosa, California + 27 more

Conditions: Covid19
Interventions: Selenium (as Selenious Acid), Placebo; Drug · Other
Lead sponsor: CHRISTUS Health; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Longview, Texas

Conditions: Gastroparesis
Interventions: Erythromycin, Azithromycin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Azithromycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Groton, Connecticut

Conditions: Pharyngitis, Tonsillitis
Interventions: azithromycin (Zithromax), placebo, azithromycin SR; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 16
States / cities: Clearwater, Florida • Boise, Idaho • Meridian, Idaho + 8 more

Conditions: Crohn Disease, Pediatric Crohns Disease
Interventions: Azithromycin, Metronidazole, Standard of Care; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 3 Years to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: San Francisco, California • Pittsburgh, Pennsylvania

Conditions: Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease
Interventions: Belumosudil, Fluticasone, Azithromycin, Prednisone, Montelukast; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Stanford, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Obesity, Induction of Labor Affected Fetus / Newborn
Interventions: Cefazolin, Placebo, Azithromycin; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Search by objective public record fields.

Treatment of Chronic Cryptosporidiosis in AIDS Patients

Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19

Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection

Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs

Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19

A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis

Study to Determine the Effect of Azasite on Corneal Surface Irregularity

A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions

Azithromycin Dose and PPROM Treatment: a Pilot Randomized Controlled Trial

Fed Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

A Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications

Azithromycin for Meibomian Gland Disease

Zoliflodacin in Uncomplicated Gonorrhoea

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis

An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy

A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults

Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term